Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04980482 | Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection | PHASE2 | COMPLETED | 43 | — | — | Oct 29, 2021 | May 21, 2025 | Apr 29, 2026 | 17 | United States, Australia +5 |
| Arm | Type | Description |
|---|---|---|
| Cohort A, Group 1 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks. |
| Cohort A, Group 2 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks. |
| Cohort B, Group 1 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks. |
| Cohort B, Group 2 | EXPERIMENTAL | AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to: NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| AB-729 | DRUG | subcutaneous injection |
| Peg-IFNα-2a | DRUG | subcutaneous injection |
Inclusion Criteria: * Chronic hepatitis B virus infection with documentation at least 6 months prior to screening * Subjects must have been receiving either TAF, TDF (or equivalent), or ETV consistently for ≥12 months prior to dosing Day 1 * HBV DNA \<LLOQ at Screening * HBsAg between 100 and 5,000...